Immunogenicity and safety of a cell culture-based quadrivalent influenza vaccine in adults: A Phase III, double-blind, multicenter, randomized, non-inferiority study

• Published in: Human vaccines & immunotherapeutics Vol. 12; no. 9; pp. 2278 - 2288
• Main Authors: Bart, Stephan, Cannon, Kevin, Herrington, Darrell, Mills, Richard, Forleo-Neto, Eduardo, Lindert, Kelly, Abdul Mateen, Ahmed
• Format: Journal Article
• Language: English
• Published: United States Taylor & Francis 01.09.2016
• Subjects: Adolescent; Adult; adults; Aged; Antibodies, Viral - blood; B-strain; cell culture; Cell Culture Techniques; Double-Blind Method; Drug-Related Side Effects and Adverse Reactions - epidemiology; Drug-Related Side Effects and Adverse Reactions - pathology; Female; Hemagglutination Inhibition Tests; Humans; influenza; Influenza Vaccines - administration & dosage; Influenza Vaccines - adverse effects; Influenza Vaccines - immunology; Influenza Vaccines - isolation & purification; Male; Middle Aged; non-inferior; phase III trial; quadrivalent influenza vaccine; Research Papers; Technology, Pharmaceutical; Young Adult; influenza; cell culture; adults; quadrivalent influenza vaccine; B-strain; phase III trial; non-inferior

Quadrivalent influenza vaccines (QIVs), which include both B lineage strains, are expected to provide broader protection than trivalent influenza vaccines (TIVs). The non-inferiority, immunogenicity, and safety of a cell culture-based investigational QIVc and 2 TIVs (TIV1c, TIV2c), in adults (≥18 y)...